Report cover image

Live Attenuated Vaccine for Chickenpox Industry Research Report 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 122 Pages
SKU # APRC20351991

Description

Summary

According to APO Research, the global Live Attenuated Vaccine for Chickenpox market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Live Attenuated Vaccine for Chickenpox is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Live Attenuated Vaccine for Chickenpox is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Live Attenuated Vaccine for Chickenpox is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Live Attenuated Vaccine for Chickenpox include GSK, BCHT, Biken, Green Cross, Keygen, Merck & Co lnc, Sanofi Pasteur, Beijing Institute of Biological Products Co., Ltd and Chengdu Institute of Biological Products Co., Ltd, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Live Attenuated Vaccine for Chickenpox, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Live Attenuated Vaccine for Chickenpox.

The report will help the Live Attenuated Vaccine for Chickenpox manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The Live Attenuated Vaccine for Chickenpox market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Live Attenuated Vaccine for Chickenpox market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Live Attenuated Vaccine for Chickenpox Segment by Company

GSK
BCHT
Biken
Green Cross
Keygen
Merck & Co lnc
Sanofi Pasteur
Beijing Institute of Biological Products Co., Ltd
Chengdu Institute of Biological Products Co., Ltd
Kexing (Dalian) Vaccine Technology Co., Ltd
Shanghai Rongsheng Biopharmaceutical Co., Ltd
Shanghai Institute of Biological Products Co., Ltd
Changchun Baike Biotechnology Co., Ltd
Changchun Qijian Biological Products Co., Ltd
Live Attenuated Vaccine for Chickenpox Segment by Type

Child
Adult
Live Attenuated Vaccine for Chickenpox Segment by Application

Hospital
Clinic
Live Attenuated Vaccine for Chickenpox Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Attenuated Vaccine for Chickenpox market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Live Attenuated Vaccine for Chickenpox and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Attenuated Vaccine for Chickenpox.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Live Attenuated Vaccine for Chickenpox manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Live Attenuated Vaccine for Chickenpox by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Live Attenuated Vaccine for Chickenpox in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Table of Contents

122 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Live Attenuated Vaccine for Chickenpox Market Size (2020-2031)
2.2.2 Global Live Attenuated Vaccine for Chickenpox Sales (2020-2031)
2.2.3 Global Live Attenuated Vaccine for Chickenpox Market Average Price (2020-2031)
2.3 Live Attenuated Vaccine for Chickenpox by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Child
2.3.3 Adult
2.4 Live Attenuated Vaccine for Chickenpox by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Hospital
2.4.3 Clinic
3 Market Competitive Landscape by Manufacturers
3.1 Global Live Attenuated Vaccine for Chickenpox Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Live Attenuated Vaccine for Chickenpox Sales (K Units) of Manufacturers (2020-2025)
3.3 Global Live Attenuated Vaccine for Chickenpox Revenue of Manufacturers (2020-2025)
3.4 Global Live Attenuated Vaccine for Chickenpox Average Price by Manufacturers (2020-2025)
3.5 Global Live Attenuated Vaccine for Chickenpox Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Live Attenuated Vaccine for Chickenpox, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Live Attenuated Vaccine for Chickenpox, Product Type & Application
3.8 Global Manufacturers of Live Attenuated Vaccine for Chickenpox, Established Date
3.9 Global Live Attenuated Vaccine for Chickenpox Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 GSK
4.1.1 GSK Company Information
4.1.2 GSK Business Overview
4.1.3 GSK Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2020-2025)
4.1.4 GSK Live Attenuated Vaccine for Chickenpox Product Portfolio
4.1.5 GSK Recent Developments
4.2 BCHT
4.2.1 BCHT Company Information
4.2.2 BCHT Business Overview
4.2.3 BCHT Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2020-2025)
4.2.4 BCHT Live Attenuated Vaccine for Chickenpox Product Portfolio
4.2.5 BCHT Recent Developments
4.3 Biken
4.3.1 Biken Company Information
4.3.2 Biken Business Overview
4.3.3 Biken Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2020-2025)
4.3.4 Biken Live Attenuated Vaccine for Chickenpox Product Portfolio
4.3.5 Biken Recent Developments
4.4 Green Cross
4.4.1 Green Cross Company Information
4.4.2 Green Cross Business Overview
4.4.3 Green Cross Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2020-2025)
4.4.4 Green Cross Live Attenuated Vaccine for Chickenpox Product Portfolio
4.4.5 Green Cross Recent Developments
4.5 Keygen
4.5.1 Keygen Company Information
4.5.2 Keygen Business Overview
4.5.3 Keygen Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2020-2025)
4.5.4 Keygen Live Attenuated Vaccine for Chickenpox Product Portfolio
4.5.5 Keygen Recent Developments
4.6 Merck & Co lnc
4.6.1 Merck & Co lnc Company Information
4.6.2 Merck & Co lnc Business Overview
4.6.3 Merck & Co lnc Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2020-2025)
4.6.4 Merck & Co lnc Live Attenuated Vaccine for Chickenpox Product Portfolio
4.6.5 Merck & Co lnc Recent Developments
4.7 Sanofi Pasteur
4.7.1 Sanofi Pasteur Company Information
4.7.2 Sanofi Pasteur Business Overview
4.7.3 Sanofi Pasteur Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2020-2025)
4.7.4 Sanofi Pasteur Live Attenuated Vaccine for Chickenpox Product Portfolio
4.7.5 Sanofi Pasteur Recent Developments
4.8 Beijing Institute of Biological Products Co., Ltd
4.8.1 Beijing Institute of Biological Products Co., Ltd Company Information
4.8.2 Beijing Institute of Biological Products Co., Ltd Business Overview
4.8.3 Beijing Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2020-2025)
4.8.4 Beijing Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
4.8.5 Beijing Institute of Biological Products Co., Ltd Recent Developments
4.9 Chengdu Institute of Biological Products Co., Ltd
4.9.1 Chengdu Institute of Biological Products Co., Ltd Company Information
4.9.2 Chengdu Institute of Biological Products Co., Ltd Business Overview
4.9.3 Chengdu Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2020-2025)
4.9.4 Chengdu Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
4.9.5 Chengdu Institute of Biological Products Co., Ltd Recent Developments
4.10 Kexing (Dalian) Vaccine Technology Co., Ltd
4.10.1 Kexing (Dalian) Vaccine Technology Co., Ltd Company Information
4.10.2 Kexing (Dalian) Vaccine Technology Co., Ltd Business Overview
4.10.3 Kexing (Dalian) Vaccine Technology Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2020-2025)
4.10.4 Kexing (Dalian) Vaccine Technology Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
4.10.5 Kexing (Dalian) Vaccine Technology Co., Ltd Recent Developments
4.11 Shanghai Rongsheng Biopharmaceutical Co., Ltd
4.11.1 Shanghai Rongsheng Biopharmaceutical Co., Ltd Company Information
4.11.2 Shanghai Rongsheng Biopharmaceutical Co., Ltd Business Overview
4.11.3 Shanghai Rongsheng Biopharmaceutical Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2020-2025)
4.11.4 Shanghai Rongsheng Biopharmaceutical Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
4.11.5 Shanghai Rongsheng Biopharmaceutical Co., Ltd Recent Developments
4.12 Shanghai Institute of Biological Products Co., Ltd
4.12.1 Shanghai Institute of Biological Products Co., Ltd Company Information
4.12.2 Shanghai Institute of Biological Products Co., Ltd Business Overview
4.12.3 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2020-2025)
4.12.4 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
4.12.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments
4.13 Changchun Baike Biotechnology Co., Ltd
4.13.1 Changchun Baike Biotechnology Co., Ltd Company Information
4.13.2 Changchun Baike Biotechnology Co., Ltd Business Overview
4.13.3 Changchun Baike Biotechnology Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2020-2025)
4.13.4 Changchun Baike Biotechnology Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
4.13.5 Changchun Baike Biotechnology Co., Ltd Recent Developments
4.14 Changchun Qijian Biological Products Co., Ltd
4.14.1 Changchun Qijian Biological Products Co., Ltd Company Information
4.14.2 Changchun Qijian Biological Products Co., Ltd Business Overview
4.14.3 Changchun Qijian Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2020-2025)
4.14.4 Changchun Qijian Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
4.14.5 Changchun Qijian Biological Products Co., Ltd Recent Developments
5 Global Live Attenuated Vaccine for Chickenpox Market Scenario by Region
5.1 Global Live Attenuated Vaccine for Chickenpox Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Live Attenuated Vaccine for Chickenpox Sales by Region: 2020-2031
5.2.1 Global Live Attenuated Vaccine for Chickenpox Sales by Region: 2020-2025
5.2.2 Global Live Attenuated Vaccine for Chickenpox Sales by Region: 2026-2031
5.3 Global Live Attenuated Vaccine for Chickenpox Revenue by Region: 2020-2031
5.3.1 Global Live Attenuated Vaccine for Chickenpox Revenue by Region: 2020-2025
5.3.2 Global Live Attenuated Vaccine for Chickenpox Revenue by Region: 2026-2031
5.4 North America Live Attenuated Vaccine for Chickenpox Market Facts & Figures by Country
5.4.1 North America Live Attenuated Vaccine for Chickenpox Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Live Attenuated Vaccine for Chickenpox Sales by Country (2020-2031)
5.4.3 North America Live Attenuated Vaccine for Chickenpox Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.5 Europe Live Attenuated Vaccine for Chickenpox Market Facts & Figures by Country
5.5.1 Europe Live Attenuated Vaccine for Chickenpox Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Live Attenuated Vaccine for Chickenpox Sales by Country (2020-2031)
5.5.3 Europe Live Attenuated Vaccine for Chickenpox Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Netherlands
5.6 Asia Pacific Live Attenuated Vaccine for Chickenpox Market Facts & Figures by Country
5.6.1 Asia Pacific Live Attenuated Vaccine for Chickenpox Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Live Attenuated Vaccine for Chickenpox Sales by Country (2020-2031)
5.6.3 Asia Pacific Live Attenuated Vaccine for Chickenpox Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Southeast Asia
5.7 South America Live Attenuated Vaccine for Chickenpox Market Facts & Figures by Country
5.7.1 South America Live Attenuated Vaccine for Chickenpox Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Live Attenuated Vaccine for Chickenpox Sales by Country (2020-2031)
5.7.3 South America Live Attenuated Vaccine for Chickenpox Revenue by Country (2020-2031)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa Live Attenuated Vaccine for Chickenpox Market Facts & Figures by Country
5.8.1 Middle East and Africa Live Attenuated Vaccine for Chickenpox Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Live Attenuated Vaccine for Chickenpox Sales by Country (2020-2031)
5.8.3 Middle East and Africa Live Attenuated Vaccine for Chickenpox Revenue by Country (2020-2031)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global Live Attenuated Vaccine for Chickenpox Sales by Type (2020-2031)
6.1.1 Global Live Attenuated Vaccine for Chickenpox Sales by Type (2020-2031) & (K Units)
6.1.2 Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Type (2020-2031)
6.2 Global Live Attenuated Vaccine for Chickenpox Revenue by Type (2020-2031)
6.2.1 Global Live Attenuated Vaccine for Chickenpox Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Type (2020-2031)
6.3 Global Live Attenuated Vaccine for Chickenpox Price by Type (2020-2031)
7 Segment by Application
7.1 Global Live Attenuated Vaccine for Chickenpox Sales by Application (2020-2031)
7.1.1 Global Live Attenuated Vaccine for Chickenpox Sales by Application (2020-2031) & (K Units)
7.1.2 Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Application (2020-2031)
7.2 Global Live Attenuated Vaccine for Chickenpox Revenue by Application (2020-2031)
7.2.1 Global Live Attenuated Vaccine for Chickenpox Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Application (2020-2031)
7.3 Global Live Attenuated Vaccine for Chickenpox Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Live Attenuated Vaccine for Chickenpox Value Chain Analysis
8.1.1 Live Attenuated Vaccine for Chickenpox Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Live Attenuated Vaccine for Chickenpox Production Mode & Process
8.2 Live Attenuated Vaccine for Chickenpox Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Live Attenuated Vaccine for Chickenpox Distributors
8.2.3 Live Attenuated Vaccine for Chickenpox Customers
9 Global Live Attenuated Vaccine for Chickenpox Analyzing Market Dynamics
9.1 Live Attenuated Vaccine for Chickenpox Industry Trends
9.2 Live Attenuated Vaccine for Chickenpox Industry Drivers
9.3 Live Attenuated Vaccine for Chickenpox Industry Opportunities and Challenges
9.4 Live Attenuated Vaccine for Chickenpox Industry Restraints
10 Report Conclusion
11 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.